Pacira BioSciences Croissance future
Future contrôle des critères 3/6
Pacira BioSciences devrait augmenter ses bénéfices et ses revenus de 35.1% et de 6.2% par an respectivement, tandis que le BPA devrait croître de croître de 104.1% par an.
Informations clés
35.1%
Taux de croissance des bénéfices
104.11%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 14.4% |
| Taux de croissance des recettes | 6.2% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Good |
| Dernière mise à jour | 19 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Seeking Alpha • May 19
Pacira BioSciences: Exparel Still Supports My Original Bull Case
Summary PCRX remains a commercial non-opioid pain company built around Exparel, Zilretta, and Iovera. That’s why I think the most important catalysts for this stock, for better or worse, will be its upcoming 2026 pipeline readouts. But I reckon that PCRX’s overdependence on Exparel remains a factor worth considering, aside from other inherent biotech risks like patents and reimbursement policies, among others. Fortunately, PCRX’s recent pullback actually offers a discount on a relatively improved company compared to the first time I covered it. As such, I reiterate my “Buy” on PCRX. Read the full article on Seeking Alpha
Mise à jour du récit • May 01
PCRX: Real World Procedure Data Will Support Future Upside Repricing
Analysts nudged their price target on Pacira BioSciences up by $2, citing slightly stronger modeled revenue growth of 17.50% and an 8.33% profit margin outlook, supported by recent real world data updates and mixed but active coverage on the stock. Analyst Commentary Recent research has been mixed, but the latest commentary highlights that bullish analysts are still finding reasons to lean constructive on Pacira BioSciences, especially around the updated revenue growth and margin framework that underpins the new price target.
Mise à jour du récit • Apr 16
PCRX: Real World Hip Data And Activist Pressure Will Shape Outlook
Analysts have reduced their Pacira BioSciences price target by $2, citing updated real world data in hip arthroplasty and revisions to growth, margin, and future P/E assumptions. Analyst Commentary Bearish analysts are flagging that updated real world hip arthroplasty data has introduced more uncertainty into Pacira BioSciences' outlook, leading to more cautious assumptions around growth, margin profile, and future P/E levels.Mise à jour du récit • Apr 01
PCRX: Higher 2026 Outlook And Activist Pressure Will Unlock Future Upside
Analysts have trimmed their Pacira BioSciences price target by $2, citing updated assumptions around faster revenue growth, a lower profit margin outlook, and a higher future P/E multiple. Analyst Commentary Despite the modest trim to the headline price target, bullish analysts see the updated assumptions as a way to reset expectations while keeping a constructive view on Pacira BioSciences.Mise à jour du récit • Mar 17
PCRX: Future Outlook Weighs Activist Board Push Against Asia Licensing Upside
Analysts have reaffirmed their $22.00 price target for Pacira BioSciences, noting small adjustments to revenue growth, profit margin assumptions, and a slightly lower future P/E multiple to reflect updated expectations for the company’s earnings profile. What's in the News DOMA Perpetual Capital Management nominated three director candidates for the 2026 annual meeting and called for the immediate replacement of CEO Frank Lee, the appointment of an interim CEO, and a formal sale process for the business (Investor activism, March 12, 2026).Mise à jour du récit • Mar 03
PCRX: Future Outlook Balances Asia Partnership Progress With Activist Pressure
Analysts have trimmed their price target on Pacira BioSciences from $24 to $22, reflecting updated assumptions that include a higher discount rate, more conservative revenue expectations, and lower projected profit margins, partly offset by a slightly higher future P/E multiple. What's in the News Issued full year 2026 earnings guidance, with total revenue expected in a range of $745 million to $770 million.Mise à jour du récit • Feb 17
PCRX: Asia Partnership Will Drive Future Upside Potential
Analysts have kept their $38.00 price target for Pacira BioSciences steady, with only small tweaks to assumptions around revenue growth, profit margins and future P/E that support this unchanged view. What's in the News Pacira BioSciences entered an agreement with LG Chem that gives LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets.Mise à jour du récit • Feb 02
PCRX: Asia Partnerships And Pipeline Progress Will Drive Future Upside Potential
Analysts have reiterated a US$38.00 price target for Pacira BioSciences, citing slightly updated assumptions for revenue growth, profit margin, and future P/E that collectively leave their overall valuation view unchanged. What's in the News Pacira entered an agreement with LG Chem, giving LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets, with Pacira receiving an upfront payment, transfer price, and tiered royalties while LG Chem handles regulatory filings in South Korea and Thailand within six months (Client Announcements).Mise à jour du récit • Jan 19
PCRX: Asia Partnership And Pipeline Advances Will Drive Future Upside Potential
Narrative Update Analysts have kept their price target for Pacira BioSciences broadly steady around $38.00, citing slightly higher modeled revenue growth, a modestly lower profit margin outlook, and a similar forward P/E assumption. What’s in the News Pacira entered an agreement with LG Chem, granting LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets.Article d’analyse • Jan 17
Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive
Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shareholders won't be pleased to see that the share price has had a very rough...Mise à jour du récit • Jan 05
PCRX: Share Buybacks And Activist Pressure Will Support Future Upside Potential
Analysts have kept their fair value estimate for Pacira BioSciences steady at $38.00. The latest price target is grounded in updated assumptions for slightly different revenue growth, profit margin expectations, and a higher future P/E multiple.Mise à jour du récit • Dec 14
PCRX: Activist Pressure And Share Buybacks Will Unlock Future Upside Potential
Analysts have modestly raised their price target on Pacira BioSciences to $38.00 from $36.00, citing expectations for slightly stronger long term profitability despite a somewhat more conservative revenue growth outlook and valuation multiple. What's in the News Activist investor DOMA Perpetual Capital Management sent a letter to Pacira's board urging the company to hire bankers and pursue a full sale process, citing persistent underperformance and overspending (Key Developments).Article d’analyse • Nov 13
Pacira BioSciences' (NASDAQ:PCRX) Strong Earnings Are Of Good Quality
When companies post strong earnings, the stock generally performs well, just like Pacira BioSciences, Inc.'s...
Mise à jour du récit • Aug 17
Policy Changes And Partnerships Will Expand Ambulatory Market Reach
The slight decrease in consensus revenue growth expectations and a lower future P/E multiple have led analysts to reduce their fair value estimate for Pacira BioSciences from $30.60 to $29.00. What's in the News Pacira completed a $50.04 million buyback, repurchasing 1,955,589 shares (4.23%) under its May 2025 authorization and previously completed a $25 million buyback (837,240 shares, 1.8%) under its May 2024 authorization.Article d’analyse • Jun 11
Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Apr 09
Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act
Summary PCRX focuses on non-opioid pain management with Exparel, Zilretta, and iovera, delivering targeted pain relief with fewer side effects. A key secular tailwind for them comes from the NOPAIN Act, which creates separate reimbursement and grows access to non-opioid therapies. Also, PCRX’s PCRX-201 is a promising new gene therapy for knee osteoarthritis, which so far has shown promising results and targets a sizeable TAM. I also like how PCRX reached important patent settlements that secure its competitive prospects with Exparel’s exclusivity until 2030. In my view, PCRX remains undervalued at these levels, which is why I consider it a “Buy” despite its inherent biotech risks. Read the full article on Seeking AlphaArticle d’analyse • Apr 07
Pacira BioSciences, Inc. (NASDAQ:PCRX) Looks Inexpensive But Perhaps Not Attractive Enough
You may think that with a price-to-sales (or "P/S") ratio of 1.5x Pacira BioSciences, Inc. ( NASDAQ:PCRX ) is a stock...Seeking Alpha • Mar 14
Pacira BioSciences: Back On An Uptrend After Positive Developments
Summary Pacira BioSciences, Inc.'s stock is up 33% since my last “Buy” rating, driven by strategic moves and market overreaction correction. The company has secured a new patent for its lead pain therapeutic, Exparel, delaying generic market entrants, and potentially protecting its market share until mid-next decade. Vertex's Journavx launch may boost awareness for non-opioid pain relief, benefiting Pacira's Exparel under the NOPAIN Act. Pacira's new five-point plan aims for growth, profitability, and pipeline expansion, positioning it for potential blockbuster revenue and market leadership. The positive steps PCRX has taken since my last note means there is no change to my “buy” thesis. Read the full article on Seeking AlphaArticle d’analyse • Jan 30
Pacira BioSciences (NASDAQ:PCRX) Has A Rock Solid Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Jan 03
Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
You may think that with a price-to-sales (or "P/S") ratio of 1.2x Pacira BioSciences, Inc. ( NASDAQ:PCRX ) is a stock...Seeking Alpha • Nov 25
Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses
Summary Pacira BioSciences markets and sells EXPAREL, a non-opioid pain relief therapy. The drug drives revenues of >$500m per annum, but a new generic version has been approved, while Pharma giant Vertex is close to having a similar drug approved. Pacira's share price has plummeted from >$80 in mid-2022 to ~$18 today, as the market sees little growth in the business and notes the competitive threats. The market may be a little too pessimistic - Vertex's drug is unproven in the market while generics may be held off for many more years. EXPAREL's peak years may still be ahead - PCRX stock could recoup some deserved value if it can share positive Q4 earnings, update on legal matters, and keep developing its pipeline. Read the full article on Seeking Alpha
Nouveau récit • Sep 24
EXPAREL's Calculated Expansion And Innovative R&D Bolster Market Dominance Amidst Challenges
Expanding EXPAREL utilization in outpatient settings and through GPO partnerships aims to enhance revenue by increasing market penetration and affordability.Article d’analyse • Sep 06
Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%
To the annoyance of some shareholders, Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shares are down a considerable 34% in...Article d’analyse • Jul 23
Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding
Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shareholders that were waiting for something to happen have been dealt a blow...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 942 | 99 | 407 | 321 | 5 |
| 12/31/2027 | 831 | 70 | 186 | 198 | 6 |
| 12/31/2026 | 767 | 34 | 145 | 158 | 6 |
| 3/31/2026 | 735 | 5 | 133 | 142 | N/A |
| 12/31/2025 | 726 | 7 | 137 | 152 | N/A |
| 9/30/2025 | 717 | 21 | 124 | 141 | N/A |
| 6/30/2025 | 706 | -127 | 117 | 135 | N/A |
| 3/31/2025 | 703 | -104 | 159 | 176 | N/A |
| 12/31/2024 | 701 | -100 | 179 | 189 | N/A |
| 9/30/2024 | 695 | -91 | 194 | 204 | N/A |
| 6/30/2024 | 690 | 64 | 185 | 194 | N/A |
| 3/31/2024 | 682 | 70 | 173 | 185 | N/A |
| 12/31/2023 | 675 | 42 | 139 | 155 | N/A |
| 9/30/2023 | 666 | 7 | 130 | 149 | N/A |
| 6/30/2023 | 669 | -5 | 127 | 147 | N/A |
| 3/31/2023 | 669 | -10 | 105 | 134 | N/A |
| 12/31/2022 | 667 | 16 | 115 | 145 | N/A |
| 9/30/2022 | 654 | 21 | 93 | 126 | N/A |
| 6/30/2022 | 614 | 39 | 102 | 144 | N/A |
| 3/31/2022 | 580 | 38 | 104 | 144 | N/A |
| 12/31/2021 | 542 | 42 | 80 | 126 | N/A |
| 9/30/2021 | 513 | 62 | 98 | 149 | N/A |
| 6/30/2021 | 503 | 174 | 83 | 129 | N/A |
| 3/31/2021 | 443 | 148 | 39 | 83 | N/A |
| 12/31/2020 | 430 | 146 | 39 | 77 | N/A |
| 9/30/2020 | 421 | 126 | 28 | 56 | N/A |
| 6/30/2020 | 408 | -10 | 13 | 35 | N/A |
| 3/31/2020 | 435 | 0 | 58 | 73 | N/A |
| 12/31/2019 | 421 | -11 | N/A | 71 | N/A |
| 9/30/2019 | 394 | 2 | N/A | 66 | N/A |
| 6/30/2019 | 372 | 8 | N/A | 64 | N/A |
| 3/31/2019 | 354 | 7 | N/A | 55 | N/A |
| 12/31/2018 | 337 | 0 | N/A | 49 | N/A |
| 9/30/2018 | 321 | -4 | N/A | 45 | N/A |
| 6/30/2018 | 305 | -11 | N/A | 25 | N/A |
| 3/31/2018 | 292 | -33 | N/A | 15 | N/A |
| 12/31/2017 | 287 | -43 | N/A | 18 | N/A |
| 9/30/2017 | 280 | -51 | N/A | 18 | N/A |
| 6/30/2017 | 281 | -66 | N/A | 33 | N/A |
| 3/31/2017 | 280 | -54 | N/A | 37 | N/A |
| 12/31/2016 | 276 | -38 | N/A | 33 | N/A |
| 9/30/2016 | 273 | -36 | N/A | 33 | N/A |
| 6/30/2016 | 267 | -11 | N/A | 26 | N/A |
| 3/31/2016 | 256 | -3 | N/A | 26 | N/A |
| 12/31/2015 | 249 | 2 | N/A | 28 | N/A |
| 9/30/2015 | 241 | 10 | N/A | 26 | N/A |
| 6/30/2015 | 231 | 4 | N/A | 29 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de PCRX ( 35.1% par an) est supérieure au taux d'épargne ( 3.5% ).
Bénéfices vs marché: Les bénéfices de PCRX ( 35.1% par an) devraient croître plus rapidement que le marché US ( 16.8% par an).
Croissance élevée des bénéfices: Les bénéfices de PCRX devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de PCRX ( 6.2% par an) devrait croître plus lentement que le marché de US ( 11.6% par an).
Croissance élevée des revenus: Le chiffre d'affaires de PCRX ( 6.2% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de PCRX devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/21 04:47 |
| Cours de l'action en fin de journée | 2026/05/21 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Pacira BioSciences, Inc. est couverte par 29 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jenna Davidner | Barclays |
| Anita Dushyanth | Berenberg |
| Gary Nachman | BMO Capital Markets Equity Research |